The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review

Advances in Medical Sciences

Volumn 61, Issue 2, 2016, Pages 331-343

  Gil, Katarzyna E ^a   Pawlak, Agnieszka ^a,b   Gil, Robert J ^a,b   Frontczak Baniewicz, Małgorzata ^b   Bil, Jacek ^a  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Coronary angiography; Dilated cardiomyopathy; Endomyocardial biopsy; Heart failure treatment

Indexed keywords

ALCOHOLIC CARDIOMYOPATHY; AMERICAN; CARDITIS; CONGESTIVE CARDIOMYOPATHY; CORONARY ANGIOGRAPHY; DIABETIC CARDIOMYOPATHY; EUROPEAN; FAMILIAL DISEASE; GENETIC ASSOCIATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HUMAN; IATROGENIC DISEASE; IRON OVERLOAD; MEDICAL SOCIETY; NONISCHEMIC CARDIOMYOPATHY; PATHOGENESIS; PERIPARTUM CARDIOMYOPATHY; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; VIRUS INFECTION; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHY, DILATED; DISEASE COURSE; INFLAMMATION; META ANALYSIS; PATHOLOGY; ULTRASTRUCTURE;

BIOPSY; CARDIOMYOPATHY, DILATED; CORONARY ANGIOGRAPHY; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MYOCARDIUM;

EID: 84984622213     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2016.07.001     Document Type: Review

References (71)

1. [1] Guzzo-Merello, G., Cobo-Marcos, M., Gallego-Delgado, M., Garcia-Pavia, P., Alcoholic cardiomyopathy. World J Cardiol 6:8 (2014), 771–781.
2. [2] Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
3. [3] Savvatis, K., Schultheiss, H.P., Tschöpe, C., Endomyocardial biopsy and ultrastructural changes in dilated cardiomyopathy: taking a ‘deeper’ look into patients’ prognosis. Eur Heart J 36:12 (2015), 708–710.
4. [4] Röttgen, R., Christiani, R., Freyhardt, P., Gutberlet, M., Schultheiss, H.P., Hamm, B., et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol 21:6 (2011), 1259–1266.
5. [5] Gutberlet, M., Spors, B., Thoma, T., Bertram, H., Denecke, T., Felix, R., et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology 246:2 (2008), 401–409.
6. [6] Friedrich, M.G., Sechtem, U., Schulz-Menger, J., Holmvang, G., Alakija, P., Cooper, L.T., et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 53:17 (2009), 1475–1487.
7. [7] Cooper, L.T., Baughman, K.L., Feldman, A.M., Frustaci, A., Jessup, M., Kuhl, U., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 28:24 (2007), 3076–3093.
8. [8] Kuhl, U., Schultheiss, H.P., Myocarditis: early biopsy allows for tailored regenerative treatment. Dtsch Arztebl Int 109:20 (2012), 361–368.
9. [9] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:8 (2012), 803–869.
10. [10] Roura, S., Planas, F., Prat-Vidal, C., Leta, R., Soler-Botija, C., Carreras, F., et al. Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. Eur J Heart Fail 9 (2007), 995–1002.
11. [11] Neglia, D., Michelassi, C., Trivieri, M.G., Sambuceti, G., Giorgetti, A., Pratali, L., et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105:2 (2002), 186–193.
12. [12] Gil, K.E., Pawlak, A., Frontczak-Baniewicz, M., Gil, R.J., Nasierowska-Guttmejer, A., The proposed new classification of coronary microcirculation as the predictor of the heart failure progression in idiopathic dilated cardiomyopathy. Cardiovasc Pathol, 2015, 10.1016/j.carpath.2015.08.001.
13. [13] Struijker-Boudier, H.A.J., Agabiti-Rosei, E., Mikrokrążenie i hemodynamika nadciśnienia tętniczego. Choroby Serca i Naczyń 6:1 (2009), 1–3.
14. [14] Ucguna, T., Basar, C., Memisogulları, R., Demirin, H., Türker, Y., Aslantas, Y., Serum visfatin and omentin levels in slow coronary flow. Rev Port Cardiol 33:12 (2014), 789–794.
15. [15] Skalidis, E.I., Parthenakis, F.I., Patrianakos, A.P., Hamilos, M.I., Vardas, P.E., Regional coronary flow and contractile reserve in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 44:10 (2004), 2027–2032.
16. [16] Dashkevich, A., Bloch, W., Antonyan, A., Goebel, H., Fries, J.U., Schlensak, C., et al. Immunohistochemical study of remodeling of myocardial lymphatic and blood microvascular structures interminal heart failure: differences between ischemic and dilated cardiomyopathy. Lymphology 43:3 (2010), 110–117.
17. [17] Małecki, M., Proczka, R., Chmiel, B., Kotlarz, A., Chorostowska-Wynimko, J., Cardiovascular gene therapy: an application of HIF-1α gene. Acta Angiol 14:4 (2008), 125–130.
18. [18] Pawlak, A., Przybylski, M., Frontczak-Baniewicz, M., Gil, K., Nasierowska-Guttmejer, A.M., Gil, R.J., Enterovirus causing progression of heart failure in a patient with a history of myocardial infarction. Hellenic J Cardiol 56:4 (2015), 332–337.
19. [19] Gil, K.E., Pawlak, A., Byczkowska, K., Michałek, A., Stan naczyń krążenia wieńcowego w nie-niedokrwiennej niewydolności serca. Problemy lekarskie 48:1 (2012), 66–69.
20. [20] Caforio, A.L., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J.R., Felix, S.B., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:33 (2013), 2636–2648.
21. [21] Kuhl, U., Schultheiss, H.P., Viral myocarditis. Swiss Med Wkly, 144, 2014, w14010.
22. [22] Pawlak, A., Gil, R.J., Kulawik, T., Pronicki, M., Karkucińska-Więckowska, A., Szymańska-Dębińska, T., et al. Type of desmin expression in cardiomyocytes – a good marker of heart failure development in idiopathic dilated cardiomyopathy. J Intern Med 272:3 (2012), 287–297.
23. [23] Pawlak, A., Gil, R.J., Grajkowska, W., Nasierowska-Guttmejer, A.M., Rzezak, J., Kulawik, T., Significance of low desmin expression in cardiomyocytes in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 111:3 (2013), 393–399.
24. [24] Kimura, A., Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy – the cause of dilated cardiomyopathy: genetic or acquired? (Genetic-side). Circ J 75 (2011), 1756–1765.
25. [25] Ortiz-Lopez, R., Li, H., Su, J., Goytia, V., Towbin JA:, Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. Circulation 95:10 (1997), 2434–2440.
26. [26] Bowles, N.E., The molecular biology of dilated cardiomyopathy. Eur Heart J 4:Suppl. I (2002), I2–I7.
27. [27] Pinto, Y.M., Elliott, P.M., Arbustini, E., Adler, Y., Anastasakis, A., Bohm, M., et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy and its implications for clinical practice: a position statement of the ESC Working Group on myocardial and pericardial diseases. Eur Heart J, 2016 pii: ehv727.
28. [28] Wasala, N.B., Bostick, B., Yue, Y., Duan, D., Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet 22:13 (2013), 2634–2641.
29. [29] Seferovic, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36:27 (2015), 1718–1727.
30. [30] Sliwa, K., Hilfiker-Kleiner, D., Petrie, M.C., Mebazaa, A., Pieske, B., Buchmann, E., et al. Current state of knowledge on aetiology, diagnosis, management and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the ESC Working Group on periartum cardiomyopathy. Eur J Heart Fail 12 (2010), 767–778.
31. [31] Gil, K.E., Drożdż, J., Pawlak, A., Michałek, A., Byczkowska, K., Koniarek, W., et al. Heart failure in female patient in peripartum period – how to determine the etiology?. Kardiol Pol 70:10 (2012), 1043–1045.
32. [32] Sliwa, K., Hilfiker-Kleiner, D., Petrie, M.C., Mebazaa, A., Pieske, B., Buchmann, E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12 (2010), 767–778.
33. [33] Shah, T., Ather, S., Bavishi, Ch., Bambhroliya, A., Ma, T., Bozkurt, B., Peripartum cardiomyopathy: a contemporary review. Methodist Debakey Cardiovasc J IV:1 (2013), 38–43.
34. [34] Gujja, P., Rosing, D.R., Tripodi, D.J., Shizukuda, Y., Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 56:13 (2010), 1001–1012.
35. [35] 79. Murphy, C.J., Oudit, G.Y., Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16:11 (2010), 888–900.
36. [36] Dennert, R., Crijns, H.J., Heymans, S., Acute viral myocarditis. Eur Heart J 29:17 (2008), 2073–2082.
37. [37] D'Ambrosio, A., Patti, G., Manzoli, A., Sinagra, G., Di Lenarda, A., Silvestri, F., et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 85:5 (2001), 499–504.
38. [38] Kühl, U., Pauschinger, M., Noutsias, M., Seeberg, B., Bock, T., Lassner, D., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111:7 (2005), 887–893.
39. [39] Kühl, U., Pauschinger, M., Bock, T., Klingel, K., Schwimmbeck, C.P., Seeberg, B., et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108:8 (2003), 945–950.
40. [40] Mahrholdt, H., Wagner, A., Deluigi, C.C., Kispert, E., Hager, S., Meinhardt, G., Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114:15 (2006), 1581–1590.
41. [41] Kühl, U., Rohde, M., Lassner, D., Gross, U.M., Escher, F., Schultheiss, H.P., miRNA as activity markers in Parvo B19 associated heart disease. Herz 37:6 (2012), 637–643.
42. [42] Kühl, U., Pauschinger, M., Seeberg, B., Lassner, D., Noutsias, M., Poller, W., et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112:13 (2005), 1965–1970.
43. [43] Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O'Connell, J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 (1996), 841–842.
44. [44] Cooper, L.T. Jr., Myocarditis. N Engl J Med 360:15 (2009), 1526–1538.
45. [45] Kindermann, I., Barth, C., Mahfoud, F., Ukena, C., Lenski, M., Yilmaz, A., et al. Update on myocarditis. J Am Coll Cardiol 59:9 (2012), 779–792.
46. [46] Schultheiss, H.P., Kühl, U., Cooper, L.T., The management of myocarditis. Eur Heart J 32:21 (2011), 2616–2625.
47. [47] Zipes, D.P., Libby, P., Bonow, R.O., Braunwald, E., Choroby serca. 1st ed., 2005, Elsevier Urban&Partner, Wroclaw [chapter 60].
48. [48] Karatolios, K., Pankuweit, S., Kisselbach Ch, Maisch, B., Inflammatory cardyomyopathy. Hellenic J Cardiol 47 (2006), 54–65.
49. [49] Grün, S., Schumm, J., Greulich, S., Wagner, A., Schneider, S., Bruder, O., et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59:18 (2012), 1604–1615.
50. [50] Basso, C., Calabrese, F., Corrado, D., Thiene, G., Postmortem diagnosis of sudden cardiac death victims. Cardiovasc Res 50 (2001), 290–300.
51. [51] Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O'Connell, J., et al. Report of the 1995 World Health Organization/International Society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation 93:5 (1996), 841–842.
52. [52] Escher, F., Lassner, D., Kuhl, U., Gross, U., Westermann, D., Poller, W., et al. Analysis of endomyocardial biopsies in suspected myocarditis – diagnostic value of left versus right ventricular biopsy. Int J Cardiol 177 (2014), 76–78.
53. [53] Gutberlet, M., Spors, B., Thoma, T., Bertram, H., Denecke, T., Felix, R., et al. Suspected chronic myocarditis AT cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology 246 (2008), 401–409.
54. [54] Caforio, A.L., Keeling, P.J., Zachara, E., Mestroni, L., Camerini, F., Mann, J.M., et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 344 (1994), 773–777.
55. [55] Caforio, A.L., Mahon, N.G., Baig, M.K., Tona, F., Murphy, R.T., Elliott, P.M., et al. Prospective familial assessment in dilated cardiomyopathy. Cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 115 (2007), 76–83.
56. [56] Lim, J.K., Glass, W.G., McDermott, D.H., Murphy, P.M., CCR5: no longer a ‘good for nothing’ gene-chemokine control of West Nile virus infection. Trends Immunol 27 (2006), 308–312.
57. [57] Maekawa, Y., Ouzounian, M., Opavsky, M.A., Liu, P.P., Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton, and innate immunity. Circulation 115 (2007), 5–8.
58. [58] Leone, O., Veinot, J.P., Angelini, A., Baandrup, U.T., Basso, C., Berry, G., et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 21 (2012), 245–274.
59. [59] Pawlak, A., Gil, R.J., Walczak, E., Seweryniak, P., Desmin expression in human cardiomyocytes and selected clinical and echocardiographic parameters in patients with chronic heart failure. Kardiol Pol 67 (2009), 955–961.
60. [60] Pawlak, A., Gil, R.J., Walczak, E., Słysz, A., Cardiomyocytes desmin abnormalities – an accurate predictor of long-term survival in patients with chronic heart failure. Kardiol Pol 67 (2009), 724–733.
61. [61] Wojnicz, R., Desmin as predictor of survival in patients with chronic heart failure. Kardiol Pol, 67(7), 2009, 734.
62. [62] Saito, T., Asai, K., Sato, S., Takano, H., Mizuno, K., Shimizu, W., Ultrastructural features of cardiomyocytes in dilated cardiomyopathy with initially decompensated heart failure as a predictor of prognosis. Eur Heart J 36:12 (2015), 724–732.
63. [63] Gullestad, L., Aass, H., Fjeld, J.G., Wikeby, L., Andreassen, A.K., Ihlen, H., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001), 220–225.
64. [64] McNamara, D.M., Holubkov, R., Starling, R.C., Dec, G.W., Loh, E., Torre-Amione, G., et al. Controlled trial of intravenous immunoglobulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001), 2254–2259.
65. [65] Kühl, U., Lassner, D., von Schlippenbach, J., Poller, W., Schultheiss, H.P., Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 60:14 (2012), 1295–1296.
66. [66] Schultheiss, H.P., Piper, C., Sowade, O., Karason, K., Kapp, J.F., Wegscheider, K., et al. The effect of subcutaneous treatment with interferon-beta-1b over 24 weeks on safety, virus elimination and clinical outcome in patients with chronic viral cardiomyopathy. 2008 late-breaking clinical trial abstracts. Circulation 118 (2008), 2309–2317.
67. [67] Krueger, G.R., Ablashi, D.V., Human herpesvirus-6: a short review of its biological behaviour. Intervirology 46 (2003), 257–269.
68. [68] Kuehl, U., Zobel, T., Schultheiss, H.P., Bock, C.T., Schmidt-Lucke, C., Therapeutic suppression of parvovirus B19 replication with the thymidine analog telbivudine improves clinical outcome in chronic myocarditis and reduces apoptosis in circulating angiogenic cells. Circulation, 126, 2012, A13892.
69. [69] Van Linthout, S., Savvatis, K., Miteva, K., Peng, J., Ringe, J., Warstat, K., et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 32:17 (2011), 2168–2178.
70. [70] Van Linthout, S., Stamm, Ch., Schultheiss, H.P., Tschope, T., Mesenchymal stem cells and inflammatory cardiomyopathy: cardiac homing and beyond. Cardiol Res Pract, 2011, 2011, 757154.
71. [71] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:10 (2009), 1006–1012.